- Home
- JAZZ vs DOX Comparison
JAZZ vs DOX Comparison
Compare JAZZ & DOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | JAZZ | DOX |
|---|---|---|
| Founded | 2003 | 1982 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 8.5B |
| IPO Year | 2007 | 1998 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | DOX |
|---|---|---|
| Price | $189.20 | $69.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 16 | 4 |
| Target Price | ★ $211.25 | $92.33 |
| AVG Volume (30 Days) | 920.6K | ★ 1.7M |
| Earning Date | 05-15-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.42% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,618,693,000.00 | N/A |
| Revenue This Year | $7.60 | $4.46 |
| Revenue Next Year | $8.34 | $3.72 |
| P/E Ratio | ★ N/A | $13.65 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $95.49 | $65.74 |
| 52 Week High | $197.47 | $94.61 |
Technical Indicators
Market Signals| Indicator | JAZZ | DOX |
|---|---|---|
| Relative Strength Index (RSI) | 70.66 | 40.53 |
| Support Level | $159.78 | $66.53 |
| Resistance Level | N/A | $85.33 |
| Average True Range (ATR) | 5.04 | 2.40 |
| MACD | 2.69 | -0.09 |
| Stochastic Oscillator | 75.97 | 47.29 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About DOX Amdocs Limited
Amdocs Ltd is a provider of software and services to communications, cable and satellite, entertainment, and media industry service providers. The Company and its subsidiaries operate in one operating segment, providing software products and services for the communications, entertainment and media industry service being designed, develop, market, support, implement, and operate its open and modular cloud offering. The company offers business support systems, operational support systems, and managed services. Geographically, it derives a majority of revenue from North America and also has a presence in Europe and the Rest of the world.